APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 3
MARCH 2014



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

34th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

34th EDITION

Cumulative Supplement 3

March 2014

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

34th EDITION

CUMULATIVE SUPPLEMENT 3
March 2014

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
WEST WARD INC (WEST WARD)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS CORP)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2013	MAR 2014	JUN 2014	SEPT 2014	DEC 2014
DRUG PRODUCTS LISTED	15711	15885			
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)			
MULTISOURCE	13194 (84.0%)	13345 (84.0%)			
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%			
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)			
EXCEPTIONS[1]	78 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	20	12			
NUMBER OF APPLICANTS	866	873			

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

	AB		MYLAN PHARMS INC	333MG	A200142	001	Mar 11, 2014	Feb NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D>	AA		MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar DISC
>A>		@		325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar DISC
>D>	AA		VINTAGE PHARMS	325MG;50MG;40MG	A040511	001	Aug 27, 2003	Mar CRLD
>A>	AA	+		325MG;50MG;40MG	A040511	001	Aug 27, 2003	Mar CRLD
		@	WATSON LABS	500MG;50MG;40MG	A040267	001	Jul 30, 1998	Jan DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

>D>			PHRENILIN WITH CAFFEINE AND CODEINE					
>D>	AB		VALEANT	325MG;50MG;40MG;30MG	A074911	001	Aug 22, 2001	Mar DISC
>A>		@		325MG;50MG;40MG;30MG	A074911	001	Aug 22, 2001	Mar DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		@	MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418	001	Jun 27, 2001	Jan DISC
	AA		VINTAGE PHARMS	325MG/15ML;7.5MG/15ML	A040894	001	Jul 19, 2011	Feb CAHN

TABLET;ORAL

ANEXSIA

		@	MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987	Jan DISC
		@		750MG;10MG	A040468	001	Oct 31, 2002	Jan DISC

ANEXSIA 7.5/650

		@	MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987	Jan DISC

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		@	MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995	Jan DISC
		@		500MG;7.5MG	A040201	001	Feb 27, 1998	Jan DISC
		@		500MG;10MG	A040201	002	Feb 27, 1998	Jan DISC
		@		650MG;10MG	A040084	004	Oct 16, 1996	Jan DISC
		@		660MG;10MG	A040084	003	Jul 29, 1996	Jan DISC
		@		750MG;7.5MG	A040084	001	Jun 01, 1995	Jan DISC
	AA		VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011	Feb CAHN
	AA			300MG;7.5MG	A090415	002	Jan 24, 2011	Feb CAHN
	AA			300MG;10MG	A090415	003	Jan 24, 2011	Feb CAHN
		@		650MG;7.5MG	A040155	001	Apr 14, 1997	Jan DISC
		@		750MG;7.5MG	A040157	001	Apr 12, 1996	Jan DISC
		@	WATSON LABS	500MG;7.5MG	A081080	001	Aug 30, 1991	Jan DISC
		@		750MG;7.5MG	A081083	001	Aug 30, 1991	Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE AND ACETAMINOPHEN

		@	MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998	Jan DISC
		@	WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997	Jan DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

		@	WATSON LABS	500MG;7.5MG	A040371	001	Dec 29, 2000	Jan DISC
		@		650MG;10MG	A040371	002	Dec 29, 2000	Jan DISC

PERCOCET

		@	VINTAGE PHARMS LLC	500MG;7.5MG	A040341	001	Jul 26, 1999	Jan DISC
		@		650MG;10MG	A040341	002	Jul 26, 1999	Jan DISC

>A>			TABLET, EXTENDED RELEASE;ORAL					
>A>			XARTEMIS XR					
>A>		+	MALLINCKRODT INC	325MG;7.5MG	N204031	001	Mar 11, 2014	Mar NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A>	AB		APOTEX INC	325MG;37.5MG	A078778	001	Apr 07, 2014	Mar NEWA

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN		INNOPHARMA LICENSING	10%	A204674	001	Feb 11, 2014	Jan NEWA

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB		CADILA PHARMS LTD	200MG	A201445	001	Mar 06, 2014	Feb NEWA

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

	+	BEDFORD	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb CRLD
	@	HIKMA MAPLE	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997	Feb DISC
	@		EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997	Feb DISC

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

>A> AP		AGILA SPECLTS	3MG/ML	A078640	001	Mar 21, 2014	Mar NEWA
AP			3MG/ML	A078686	001	May 13, 2009	Feb CAHN
>A> AP		HOSPIRA INC	3MG/ML	A203883	001	Mar 24, 2014	Mar NEWA
>A> AP		SAGENT STRIDES	3MG/ML	A090212	001	Mar 28, 2014	Mar NEWA

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

AB		VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb CAHN
AB			0.5MG	A090248	002	Sep 17, 2010	Feb CAHN
AB			1MG	A090248	003	Sep 17, 2010	Feb CAHN
AB			2MG	A090248	004	Sep 17, 2010	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB		ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan CAHN
	@		0.5MG	A077979	001	Feb 28, 2007	Jan CAHN
AB			1MG	A077725	002	Jul 31, 2006	Jan CAHN
	@		1MG	A077979	002	Feb 28, 2007	Jan CAHN
AB			2MG	A077725	004	Jul 31, 2006	Jan CAHN
	@		2MG	A077979	003	Feb 28, 2007	Jan CAHN
AB			3MG	A077725	003	Jul 31, 2006	Jan CAHN
	@		3MG	A077979	004	Feb 28, 2007	Jan CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB	+	SANDOZ	100MG	A071293	001	Feb 18, 1987	Feb CRLD
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Feb CRLD

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	@	PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	Feb DISC
	@		EQ 5MG BASE	A078131	002	Sep 04, 2007	Feb DISC
	@		EQ 10MG BASE	A078131	003	Sep 04, 2007	Feb DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014	Feb NEWA
AB			EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014	Feb NEWA
AB			EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014	Feb NEWA
AB			EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014	Feb NEWA
AB			EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014	Feb NEWA
AB			EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014	Feb NEWA
AB			EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014	Feb NEWA
AB			EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014	Feb NEWA
AB			EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014	Feb NEWA
AB			EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014	Feb NEWA
AB			EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014	Feb NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

>A>	AP	UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204496	001	Mar 28, 2014	Mar	NEWA
	AP	WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204506	001	Feb 07, 2014	Jan	NEWA

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

	AB	SANDOZ	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A202588	001	Mar 04, 2014	Feb	NEWA

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

>A> CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

>A> OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

>A>	+	GASTROENTERO	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Mar	CDFR

>D> CAPSULE, TABLET, CAPSULE, DELAYED RELEASE, TABLET;ORAL

>D> OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

>D>	+	GASTROENTERO	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Mar	CDFR

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

>A>	AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Mar	NEWA
	AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062719	002	May 12, 1987	Feb	CAHN
	AP		EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993	Feb	CAHN
	AP		EQ 10GM BASE/VIAL	A201404	001	Dec 20, 2013	Jan	CPOT
	AP		EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Feb	CAHN
	AP		EQ 250MG BASE/VIAL	A062719	001	May 12, 1987	Feb	CAHN
	AP		EQ 500MG BASE/VIAL	A062719	003	May 12, 1987	Feb	CAHN
>A>	AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Mar	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Mar	NEWA
>A>	AP		EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Mar	NEWA
>A>	AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Mar	NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

>A>	AP	AGILA SPECLTS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Mar	NEWA
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Mar	NEWA
>A>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Mar	NEWA
	AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005	Feb	CAHN
	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005	Feb	CAHN
	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006	Feb	CAHN

>A> APREMILAST

>A> TABLET;ORAL

>A> OTEZLA

>A>		CELGENE CORP	10MG	N205437	001	Mar 21, 2014	Mar	NEWA
>A>			20MG	N205437	002	Mar 21, 2014	Mar	NEWA
>A>	+		30MG	N205437	003	Mar 21, 2014	Mar	NEWA

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

		FOREST LABS INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CAHN
	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

>D>	AB	WATSON LABS	325MG;50MG;40MG;30MG	A074359	001	Aug 31, 1995	Mar	DISC
>A>	@		325MG;50MG;40MG;30MG	A074359	001	Aug 31, 1995	Mar	DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

>D>	AB		STEVENS J	385MG;30MG;25MG	A074988	001	Apr 30, 1999	Mar DISC
>A>		@		385MG;30MG;25MG	A074988	001	Apr 30, 1999	Mar DISC
>D>	AB			770MG;60MG;50MG	A074988	002	Apr 30, 1999	Mar DISC
>A>		@		770MG;60MG;50MG	A074988	002	Apr 30, 1999	Mar DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

>D>	AB		MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar DISC
>A>		@		325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar DISC
>D>	AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Mar DISC
>A>		@		325MG;200MG;16MG	A040283	001	Dec 29, 1998	Mar DISC

ATOVAQUONE

SUSPENSION;ORAL

>A>			ATOVAQUONE					
>A>	AB		AMNEAL PHARMS	750MG/5ML	A202960	001	Mar 18, 2014	Mar NEWA
			MEPRON					
>D>		+	GLAXOSMITHKLINE LLC	750MG/5ML	N020500	001	Feb 08, 1995	Mar CFTG
>A>	AB	+		750MG/5ML	N020500	001	Feb 08, 1995	Mar CFTG

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

			ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Feb CAHN
		+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Feb CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

			ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Feb CAHN
		+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Feb CAHN

BACITRACIN

OINTMENT;OPHTHALMIC

			BACITRACIN					
		+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Feb CTEC

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

	AB		MYLAN	5MG;40MG	A078688	001	Feb 15, 2008	Jan CTNA
	AB			5MG;80MG	A078688	002	Feb 15, 2008	Jan CTNA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

>D>	AB		VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Mar CRLD
>A>	AB	+		5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Mar CRLD
>D>	BT	+		5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Mar CTEC
>A>		+		5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Mar CTEC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL

LOTRISONE

	AB	+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Jan CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

DUVOID

>D>	AA		WELLSPRING PHARM	10MG	A086262	001		Mar DISC
>A>		@		10MG	A086262	001		Mar DISC
>D>	AA			25MG	A086263	001		Mar DISC
>A>		@		25MG	A086263	001		Mar DISC
>D>	AA			50MG	A085882	003		Mar DISC
>A>		@		50MG	A085882	003		Mar DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

>D>		+	APTALIS PHARMA US	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar CAHN
>A>		+	FOREST RES INST INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar CAHN

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY

	AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan CFTG

BROMFENAC SODIUM

	AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan CTEC
	AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan NEWA
	AT1		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan CTEC

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

>A>	AB		BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL

UCERIS

>D>		+	SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Mar CAHN
		+		9MG	N203634	001	Jan 14, 2013	Feb CAHN
>A>		+	SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Mar CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

		@	WATSON LABS	300MG	A077715	002	Jun 13, 2007	Feb DISC
	AB3		ZYDUS PHARMS USA INC	300MG	A201567	001	Jan 17, 2014	Jan NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

	AB		ZYDUS PHARMS USA INC	5MG	A078888	001	Feb 07, 2014	Jan NEWA
	AB			10MG	A078888	002	Feb 07, 2014	Jan NEWA
	AB			15MG	A078888	003	Feb 07, 2014	Jan NEWA
	AB			30MG	A078888	004	Feb 07, 2014	Jan NEWA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

	AP		EXELA PHARMA SCIENCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233	001	Sep 21, 2006	Feb CAHN

SOLUTION;ORAL

CAFFEINE CITRATE

	AA		EXELA PHARMA SCS LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Feb CAHN

CALCITRIOL

INJECTABLE;INJECTION

CALCITRIOL

		@	TEVA PARENTERAL	0.002MG/ML	A075823	002	Mar 31, 2003	Feb DISC

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

>D>	AB		WATSON LABS	12.5MG	A074451	001	Feb 13, 1996	Mar DISC
>A>		@		12.5MG	A074451	001	Feb 13, 1996	Mar DISC
>D>	AB			25MG	A074451	002	Feb 13, 1996	Mar DISC
>A>		@		25MG	A074451	002	Feb 13, 1996	Mar DISC
>D>	AB			50MG	A074451	003	Feb 13, 1996	Mar DISC
>A>		@		50MG	A074451	003	Feb 13, 1996	Mar DISC
>D>	AB			100MG	A074451	004	Feb 13, 1996	Mar DISC
>A>		@		100MG	A074451	004	Feb 13, 1996	Mar DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

>D>			CAPOZIDE 25/15					
>D>	AB		APOTHECON	25MG;15MG	N018709	001	Oct 12, 1984	Mar DISC
>A>		@		25MG;15MG	N018709	001	Oct 12, 1984	Mar DISC

			TABLET;ORAL						
>D>			CAPOZIDE 25/25						
>D>	AB	+	APOTHECON	25MG;25MG	N018709	002	Oct 12, 1984	Mar DISC	
>A>		@		25MG;25MG	N018709	002	Oct 12, 1984	Mar DISC	
>D>			CAPOZIDE 50/15						
>D>	AB	+	APOTHECON	50MG;15MG	N018709	004	Oct 12, 1984	Mar DISC	
>A>		@		50MG;15MG	N018709	004	Oct 12, 1984	Mar DISC	
>D>			CAPOZIDE 50/25						
>D>	AB		APOTHECON	50MG;25MG	N018709	003	Oct 12, 1984	Mar DISC	
>A>		@		50MG;25MG	N018709	003	Oct 12, 1984	Mar DISC	
			CAPTOPRIL AND HYDROCHLOROTHIAZIDE						
>D>	AB		MYLAN	25MG;25MG	A074896	002	Dec 29, 1997	Mar CRLD	
>A>	AB	+		25MG;25MG	A074896	002	Dec 29, 1997	Mar CRLD	
>D>	AB			50MG;15MG	A074896	004	Dec 29, 1997	Mar CRLD	
>A>	AB	+		50MG;15MG	A074896	004	Dec 29, 1997	Mar CRLD	
			CARBIDOPA						
			TABLET;ORAL						
			CARBIDOPA						
	AB		AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Feb NEWA	
			LODOSYN						
	AB	+	ATON	25MG	N017830	001		Feb CFTG	
			CARBINOXAMINE MALEATE						
			SOLUTION;ORAL						
			CARBINOXAMINE MALEATE						
	AA		VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb CAHN	
			TABLET;ORAL						
			CARBINOXAMINE MALEATE						
	AA		VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb CAHN	
			CARBOPLATIN						
			INJECTABLE;IV (INFUSION)						
			CARBOPLATIN						
	AP	+	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb CAHN	
	AP	+		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb CAHN	
	AP	+		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb CAHN	
	AP	+		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb CAHN	
			CARISOPRODOL						
			TABLET;ORAL						
			CARISOPRODOL						
	AA		SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan NEWA	
			CEFACLOR						
			FOR SUSPENSION;ORAL						
			CEFACLOR						
	AB	+	YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan CRLD	
			CEFADROXIL/CEFADROXIL HEMIHYDRATE						
			FOR SUSPENSION;ORAL						
			CEFADROXIL						
		@	ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan CAHN	
		@		EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan CAHN	
		@		EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan CAHN	
		@		EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989	Jan CAHN	
		@		EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Jan CAHN	
			CEFAZOLIN SODIUM						
			INJECTABLE;INJECTION						
			CEFAZOLIN SODIUM						
>D>	AP		STERI PHARMA	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar DISC	
>A>		@		EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar DISC	
			CEFTRIAXONE SODIUM						
			INJECTABLE;INJECTION						
			CEFTRIAXONE						
	AP		AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb CAHN	

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

>D>	AB	STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar DISC
>A>		@	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar DISC

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

	@ ANI PHARMS INC	100MG	A088768	001	Oct 11, 1984	Jan CAHN
	@	100MG	A088812	001	Oct 19, 1984	Jan CAHN
	@	100MG	A088840	001	Oct 25, 1984	Feb CAHN
	@	100MG	A088918	001	Oct 16, 1984	Jan CAHN
AB		100MG	A088921	001	Apr 12, 1985	Jan CAHN
	@	100MG	A089446	001	Nov 17, 1986	Jan CAHN
	@	250MG	A088813	001	Oct 19, 1984	Jan CAHN
	@	250MG	A088919	001	Oct 16, 1984	Jan CAHN
AB		250MG	A088922	001	Apr 12, 1985	Jan CAHN
	@	250MG	A089447	001	Nov 17, 1986	Jan CAHN

GLUCAMIDE

	@ ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Jan CAHN

CICLOPIROX

CREAM;TOPICAL

CICLOPIROX

>D>	@ TARO	0.77%	A076790	001	Apr 12, 2005	Mar CMFD
>A>	AB	0.77%	A076790	001	Apr 12, 2005	Mar CMFD
	@	0.77%	A076790	001	Apr 12, 2005	Feb DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA	ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan CAHN
	@	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb CAHN
	@	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan CAHN

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

AB	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb CFTG
AB	+	500MG/5ML	N020780	002	Sep 26, 1997	Feb CFTG

CIPROFLOXACIN

AB	LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb NEWA
AB		500MG/5ML	A200563	002	Mar 05, 2014	Feb NEWA

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP	PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb NEWA

CLINDAMYCIN PHOSPHATE

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

	@ VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb NEWA
AP		5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

>A>	AB	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar NEWA
>A>	AB		0.2MG	A202983	002	Apr 02, 2014	Mar NEWA

CLOPIDOGREL

TABLET;ORAL

CLOPIDOGREL

>A>	AB	AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar	NEWA

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

	AB	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb	NEWA
	AB	MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan	NEWA

CLOZAPINE

TABLET;ORAL

CLOZAPINE

>D>		IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar	CTEC
>A>	AB		12.5MG	A074949	003	Jul 31, 2003	Mar	CTEC
>D>			200MG	A076809	001	Dec 16, 2005	Mar	CTEC
>A>	AB		200MG	A076809	001	Dec 16, 2005	Mar	CTEC
>A>	AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar	NEWA
>A>	AB		50MG	A075417	004	Apr 15, 2010	Mar	NEWA
>A>	AB		200MG	A075417	005	Apr 15, 2010	Mar	NEWA

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

	AP	SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb	NEWA

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;IV (INFUSION)

VAPRISOL

	@	CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Feb	CAHN

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+		CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Feb	CAHN

DANTROLENE SODIUM

CAPSULE;ORAL

DANTRIUM

>D>	AB	JHP PHARMS	25MG	N017443	001		Mar	CAHN
>D>	AB		50MG	N017443	003		Mar	CAHN
>D>	AB	+	100MG	N017443	002		Mar	CAHN
>A>	AB	PAR STERILE PRODUCTS	25MG	N017443	001		Mar	CAHN
>A>	AB		50MG	N017443	003		Mar	CAHN
>A>	AB	+	100MG	N017443	002		Mar	CAHN

INJECTABLE;INJECTION

>D>

DANTROLENE SODIUM

>D>	AP	US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar	CTNA

>A>

REVONTO

>A>	AP	US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar	CTNA

DAPAGLIFLOZIN

TABLET;ORAL

FARXIGA

		ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb	CAHN
	+		10MG	N202293	002	Jan 08, 2014	Feb	CAHN
		BRISTOL MYERS SQUIBB	5MG	N202293	001	Jan 08, 2014	Jan	NEWA
	+		10MG	N202293	002	Jan 08, 2014	Jan	NEWA

DECITABINE

POWDER;INTRAVENOUS

DECITABINE

	+	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014	Jan	NEWA

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

	@	ANI PHARMS INC	25MG	A071800	001	Dec 08, 1987	Jan	CAHN
	@		50MG	A071801	001	Dec 08, 1987	Jan	CAHN
	@		75MG	A071802	001	Dec 08, 1987	Jan	CAHN
	@		100MG	A071803	001	May 29, 1997	Feb	CAHN
	@		150MG	A071804	001	May 29, 1997	Feb	CAHN

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB		SUN PHARMA GLOBAL	0.01MG/SPRAY	A	078271	001	Dec 23, 2013	Jan CMS2

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

BC		SUN PHARMA GLOBAL	50MG	N	205583	001	Jan 28, 2014	Jan NEWA
BC	+		100MG	N	205583	002	Jan 28, 2014	Jan NEWA

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE FUMARATE

	+	SUN PHARMA GLOBAL	EQ 50MG BASE	N	205583	001	Jan 28, 2014	Feb CTEC
	+		EQ 100MG BASE	N	205583	002	Jan 28, 2014	Feb CTEC

DEXCHLORPHENIRAMINE MALEATE

TABLET;ORAL

DEXCHLORPHENIRAMINE MALEATE

	@	ANI PHARMS INC	2MG	A	088682	001	Jan 17, 1986	Jan CAHN

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		COREPHARMA	5MG	A	090652	001	Mar 07, 2014	Feb NEWA
AA			10MG	A	090652	002	Mar 07, 2014	Feb NEWA

DIAZEPAM

CONCENTRATE;ORAL

>A>			DIAZEPAM						
>A>	AA		LANNETT HOLDINGS INC	5MG/ML	A	204433	001	Apr 14, 2014	Mar NEWA

DIAZEPAM INTENSOL

>D>		+	ROXANE	5MG/ML	A	071415	001	Apr 03, 1987	Mar CFTG
>A>	AA	+		5MG/ML	A	071415	001	Apr 03, 1987	Mar CFTG

TABLET;ORAL

DIAZEPAM

>D>	AB		DAVA PHARMS INC	2MG	A	070226	001	Sep 26, 1985	Mar DISC
>A>		@		2MG	A	070226	001	Sep 26, 1985	Mar DISC

DICLOFENAC POTASSIUM

FOR SOLUTION;ORAL

CAMBIA

	+	DEPOMED INC	50MG	N	022165	001	Jun 17, 2009	Jan CAHN

DICLOFENAC SODIUM

SOLUTION;TOPICAL

PENNSAID

	+	MALLINCKRODT INC	2%	N	204623	001	Jan 16, 2014	Jan NEWA

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

>A>	AB		EAGLE PHARMS	50MG;0.2MG	A	200540	001	Mar 14, 2014	Mar NEWA
>A>	AB			75MG;0.2MG	A	200540	002	Mar 14, 2014	Mar NEWA

DIGOXIN

TABLET;ORAL

LANOXIN

		COVIS PHARMA	0.0625MG	N	020405	001	Sep 30, 1997	Jan CMFD
			0.1875MG	N	020405	003	Sep 30, 1997	Jan CMFD

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

>D>	AB4		NESHER PHARMS	120MG	A	076563	002	Sep 12, 2006	Mar DISC
>A>		@		120MG	A	076563	002	Sep 12, 2006	Mar DISC
>D>	AB4			180MG	A	076563	003	Sep 12, 2006	Mar DISC
>A>		@		180MG	A	076563	003	Sep 12, 2006	Mar DISC
>D>	AB4			240MG	A	076563	004	Sep 12, 2006	Mar DISC
>A>		@		240MG	A	076563	004	Sep 12, 2006	Mar DISC

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

>D>	AB4		300MG	A076563	005	Sep 12, 2006	Mar DISC
>A>		@	300MG	A076563	005	Sep 12, 2006	Mar DISC
>D>	AB4		360MG	A076563	006	Sep 12, 2006	Mar DISC
>A>		@	360MG	A076563	006	Sep 12, 2006	Mar DISC
>D>	AB4		420MG	A076563	001	Sep 12, 2006	Mar DISC
>A>		@	420MG	A076563	001	Sep 12, 2006	Mar DISC

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

		@ AGILA SPECLTS	5MG/ML	A075375	001	Sep 30, 1999	Feb CAHN

DIPYRIDAMOLE

TABLET;ORAL
DIPYRIDAMOLE

>D>	AB	GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991	Mar DISC
>A>		@	25MG	A088999	001	Feb 05, 1991	Mar DISC
>D>	AB		50MG	A089000	001	Feb 05, 1991	Mar DISC
>A>		@	50MG	A089000	001	Feb 05, 1991	Mar DISC
>D>	AB		75MG	A089001	001	Feb 05, 1991	Mar DISC
>A>		@	75MG	A089001	001	Feb 05, 1991	Mar DISC

DISULFIRAM

TABLET;ORAL
DISULFIRAM

	AB	ROXANE	250MG	A202652	001	Feb 05, 2014	Jan NEWA
	AB		500MG	A202652	002	Feb 05, 2014	Jan NEWA

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

>A>		PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Mar NEWA
>A>			80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Mar NEWA
>A>			130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Mar NEWA
>A>			200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

	AB	MACLEODS PHARMS LTD	23MG	A202631	001	Jan 22, 2014	Jan NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION
DOXERCALCIFEROL

	AP	SANDOZ	4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
DOXORUBICIN HYDROCHLORIDE

	AP	PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995	Feb CAHN
	AP		10MG/VIAL	A063097	001	May 21, 1990	Feb CAHN
	AP		20MG/VIAL	A063097	002	May 21, 1990	Feb CAHN
	AP		50MG/VIAL	A063097	003	May 21, 1990	Feb CAHN
	AP		200MG/100ML	A063336	004	Feb 28, 1995	Feb CAHN

DOXYCYCLINE

CAPSULE;ORAL
DOXYCYCLINE

	AB	LUPIN LTD	EQ 50MG BASE	A204234	001	Mar 05, 2014	Feb NEWA
	AB		EQ 75MG BASE	A204234	002	Mar 05, 2014	Feb NEWA
	AB		EQ 100MG BASE	A204234	003	Mar 05, 2014	Feb NEWA

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL
DORYX

	AB	MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb CRLD
	+		EQ 200MG BASE	N050795	005	Apr 11, 2013	Feb CRLD

DROXIDOPA

CAPSULE;ORAL

NORTHERA

		CHELSEA THERAPS INC	100MG	N203202	001	Feb 18, 2014	Feb NEWA
			200MG	N203202	002	Feb 18, 2014	Feb NEWA
	+		300MG	N203202	003	Feb 18, 2014	Feb NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Feb NEWA

JALYN

AB	+	GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb CFTG

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

	+	VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Feb CAHN

CREAM;TOPICAL

SPECTAZOLE

	@	MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jan CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

EPIRUBICIN HYDROCHLORIDE

>D> AP		MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Mar DISC
>A>	@		50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Mar DISC
>D> AP			200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Mar DISC
>A>	@		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Mar DISC

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROMYCIN STEARATE

	@	ANI PHARMS INC	EQ 250MG BASE	A061461	001		Feb CAHN
	@		EQ 250MG BASE	A061591	001		Jan CAHN
	@		EQ 500MG BASE	A061461	002		Feb CAHN
	@		EQ 500MG BASE	A063179	001	May 15, 1990	Feb CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

AB		TEVA PHARMS USA	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb CAHN
AB			EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb CAHN
AB			EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

NEXIUM

>A>		ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Mar NEWA

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

>A> AB		DR REDDYS LABS LTD	1MG	A091024	001	Apr 15, 2014	Mar NEWA
>A> AB			2MG	A091024	002	Apr 15, 2014	Mar NEWA
>A> AB			3MG	A091024	003	Apr 15, 2014	Mar NEWA
>A> AB		GLENMARK GENERICS	1MG	A091166	001	Apr 15, 2014	Mar NEWA
>A> AB			2MG	A091166	002	Apr 15, 2014	Mar NEWA
>A> AB			3MG	A091166	003	Apr 15, 2014	Mar NEWA
>D>	@	LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Mar CMFD
>A> AB			1MG	A091124	001	Sep 13, 2011	Mar CMFD
>D>	@		2MG	A091124	002	Sep 13, 2011	Mar CMFD
>A> AB			2MG	A091124	002	Sep 13, 2011	Mar CMFD
>D>	@		3MG	A091124	003	Sep 13, 2011	Mar CMFD
>A> AB			3MG	A091124	003	Sep 13, 2011	Mar CMFD
>A> AB		ROXANE	1MG	A091153	001	Apr 15, 2014	Mar NEWA
>A> AB			2MG	A091153	002	Apr 15, 2014	Mar NEWA
>A> AB			3MG	A091153	003	Apr 15, 2014	Mar NEWA
AB		TEVA	1MG	A091169	001	May 23, 2011	Jan CMFD
AB			2MG	A091169	002	May 23, 2011	Jan CMFD
AB			3MG	A091169	003	May 23, 2011	Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

	AB1		HAUPT PHARMA	0.02MG;0.1MG	A201108	001	Feb 05, 2014	Jan NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ORTHO EVRA

>A>	AB	+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar CFTG
>A>		+		0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar CPOT
>D>		+		0.75MG;6MG	N021180	001	Nov 20, 2001	Mar CPOT

XULANE

>A>	AB		MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21

GILDESS 1.5/30

>A>	AB		VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012	Mar NEWA

GILDESS 1/20

>A>	AB		VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Mar NEWA

LARIN 1.5/30

>A>	AB		NOVAST LABS LTD	0.03MG;1.5MG	A202996	001	Mar 20, 2014	Mar NEWA

ETODOLAC

CAPSULE;ORAL

ETODOLAC

		@	ANI PHARMS INC	200MG	A074899	001	Jul 08, 1997	Feb CAHN
		@		200MG	A075126	001	Sep 16, 1999	Jan CAHN
		@		300MG	A074899	002	Jul 08, 1997	Feb CAHN
	AB			300MG	A075126	002	Sep 16, 1999	Jan CAHN

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

	AP		AGILA SPECLTS	2MG/ML	A078289	001	Jan 02, 2009	Feb CAHN

ETOPOSIDE

INJECTABLE;INJECTION

ETOPOSIDE

		@	PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996	Feb CAHN

EXENATIDE SYNTHETIC

INJECTABLE;SUBCUTANEOUS

BYETTA

>D>		+	AMYLIN	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar CAHN
>D>		+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar CAHN
>A>		+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar CAHN
>A>		+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar CAHN

FAMOTIDINE

INJECTABLE;INJECTION

FAMOTIDINE PRESERVATIVE FREE

	AP		BEDFORD LABS	10MG/ML	A075825	001	Apr 17, 2001	Feb CAHN

FENOFIBRATE

TABLET;ORAL

FENOGLIDE

			SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Feb CAHN
		+		120MG	N022118	002	Aug 10, 2007	Feb CAHN

FLORBETABEN F-18

SOLUTION;INTRAVENOUS

NEURACEQ

>A>		+	PIRAMAL IMAGING	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Mar NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014	Jan NEWA
AP		LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan NEWA
	@	WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004	Feb DISC
AP		WUSM CYCLOTRON	20-300mCi/ML	A203935	001	Feb 05, 2014	Jan NEWA

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB		HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011	Jan CAHN
AB			0.1MG	A091302	001	Jul 22, 2011	Jan CAHN
AB			0.1MG	A091302	001	Jul 22, 2011	Jan CAHN
AB			0.1MG	A091302	001	Jul 22, 2011	Jan CAHN

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROSPAN HFA

>D>	+	ACTON PHARMS	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Mar CAHN
>A>	+	MEDA PHARMS INC	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Mar CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB2		ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Jan CAHN
AB2			EQ 20MG BASE	A076287	002	May 20, 2008	Jan CAHN

TABLET;ORAL

SARAFEM

AB1		WARNER CHILCOTT LLC	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CFTG
AB1			EQ 15MG BASE	N021860	002	May 19, 2006	Jan CFTG
AB1	+		EQ 20MG BASE	N021860	003	May 19, 2006	Jan CFTG

SELFEMRA

AB1		TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Jan NEWA
AB1			EQ 15MG BASE	A200151	002	Feb 03, 2014	Jan NEWA
AB1			EQ 20MG BASE	A200151	003	Feb 03, 2014	Jan NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

	@	ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993	Feb CAHN

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA		CADILA PHARMS LTD	1 MG	A202437	001	Jan 27, 2014	Jan NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb CAIN
AB	+		20MG;12.5MG	A079025	002	Sep 17, 2010	Feb CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	+	EMCURE PHARMS INDIA	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan CRLD

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

CEREBYX

AP		PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb CMFD

FOSPHENYTOIN SODIUM

AP		AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb CAHN

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

	AP		CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	Jan NEWA

TABLET;ORAL

FUROSEMIDE

>A>	AB		CARACO	20MG	A091258	001	Apr 01, 2014	Mar NEWA
>A>	AB			40MG	A091258	002	Apr 01, 2014	Mar NEWA
>A>	AB			80MG	A091258	003	Apr 01, 2014	Mar NEWA

GABAPENTIN

TABLET;ORAL

GABAPENTIN

	AB		ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb CAHN
	AB			800MG	A203244	001	Jul 12, 2013	Feb CAHN

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

		+	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Jan NEWA

GLYCOPYRROLATE

TABLET;ORAL

GLYCOPYRROLATE

	AA		STASON PHARMS	1MG	A091182	001	Feb 03, 2014	Jan NEWA
	AA			2MG	A091182	002	Feb 03, 2014	Jan NEWA
	AA		VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Feb CAHN
	AA			2MG	A090020	002	Oct 19, 2011	Feb CAHN

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

			ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995	Jan CAHN
>A>		@		EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar CAHN
		+		EQ 8MG BASE	A074149	002	Apr 07, 1995	Jan CAHN
>A>		@		EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar CAHN
>D>		@	TEVA PHARMS	EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar CAHN
>D>		@		EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar CAHN

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

	AO		AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb CMFD
	AO			EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb CMFD

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

>A>		+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011	Mar NEWA
>D>	AP		HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar CRLD
>A>		+		5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar CRLD
>D>			PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar CRLD
>A>		+		1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar CRLD
>D>				5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar CRLD
>A>		+		5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar CRLD
>D>				10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar CRLD
>A>		+		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar CRLD

HEPARIN SODIUM IN PLASTIC CONTAINER

>D>	AP	+	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar CTEC
>A>		+		1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar CTEC
>D>	AP	+		10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar CTEC
>A>		+		10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar CTEC
>D>	AP	+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar CTEC
>A>		+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar CTEC

HEPARIN SODIUM PRESERVATIVE FREE

>A>		+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar NEWA
>D>	AP	+	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987	Mar CTEC
>A>		+		10,000 UNITS/ML	A089522	001	May 04, 1987	Mar CTEC
>D>			PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar CRLD
>A>		+		1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar CRLD

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

>A>	AB		CARACO	12.5MG	A090651	001	Apr 07, 2014	Mar NEWA

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>A>			MYLAN	15MG;250MG	A070265	002	Jan 23, 1986	Mar CMS1

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHOLROTHIAZIDE

	AB		INDICUS PHARMA	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Feb NEWA
	AB			12.5MG;15MG	A202150	002	Mar 07, 2014	Feb NEWA
	AB			25MG;15MG	A202150	003	Mar 07, 2014	Feb NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB		MYLAN	25MG;40MG	A070947	002	Mar 04, 1987	Mar CMS1

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

MICARDIS HCT

	AB		BOEHRINGER INGELHEIM	12.5MG;40MG	N021162	001	Nov 17, 2000	Feb CFTG
	AB			12.5MG;80MG	N021162	002	Nov 17, 2000	Feb CFTG
	AB	+		25MG;80MG	N021162	003	Apr 19, 2004	Feb CFTG

TELMISARTAN AND HYDROCHLOROTHIAZIDE

	AB		ALEMBIC PHARMS LTD	12.5MG;40MG	A203010	001	Feb 25, 2014	Feb NEWA
	AB			12.5MG;80MG	A203010	002	Feb 25, 2014	Feb NEWA
	AB			25MG;80MG	A203010	003	Feb 25, 2014	Feb NEWA
	AB		MYLAN PHARMS INC	12.5MG;40MG	A091648	001	Feb 25, 2014	Feb NEWA
	AB			12.5MG;80MG	A091648	002	Feb 25, 2014	Feb NEWA
	AB			25MG;80MG	A091648	003	Feb 25, 2014	Feb NEWA
	AB		TORRENT PHARMS LTD	12.5MG;40MG	A201192	001	Feb 25, 2014	Feb NEWA
	AB			12.5MG;80MG	A201192	002	Feb 25, 2014	Feb NEWA
	AB			25MG;80MG	A201192	003	Feb 25, 2014	Feb NEWA

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

>D>	AT		TARO	1%	A086155	001		Mar DISC
>A>			@	1%	A086155	001		Mar DISC

LOTION;TOPICAL

>D>			ALA-CORT					
>D>	AT		CROWN LABS	1%	A083201	001		Mar DISC
>A>			@	1%	A083201	001		Mar DISC
>D>			NUTRACORT					
>D>	AT		DOW PHARM	1%	A080443	003		Mar DISC
>A>			@	1%	A080443	003		Mar DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

			@ VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988	Feb CAHN

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

BONIVA

	AP	+	ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb CFTG

IBANDRONATE SODIUM

	AP		SUN PHARM INDS LTD	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	Feb NEWA

INDOMETHACIN

CAPSULE;ORAL

TIVORBEX

			IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014	Feb NEWA
		+		40MG	N204768	002	Feb 24, 2014	Feb NEWA

CAPSULE, EXTENDED RELEASE;ORAL
INDOMETHACIN

>A>	AB		MYLAN PHARMS INC	75MG		A202139	001	Mar 20, 2014	Mar NEWA

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXTOUCH

		+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)		N020986	005	Oct 31, 2013	Feb NEWA

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXTOUCH

		+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)		N021536	005	Oct 31, 2013	Feb NEWA

IPRATROPIUM BROMIDE

SOLUTION;INHALATION
IPRATROPIUM BROMIDE

>D>	AN	+	DEY	0.02%		A074755	001	Jan 10, 1997	Mar CAHN
>A>	AN	+	MYLAN SPECLT	0.02%		A074755	001	Jan 10, 1997	Mar CAHN

ISOFLURANE

LIQUID;INHALATION
ISOFLURANE

	AN		PIRAMAL ENT	99.9%		A074502	001	Jun 27, 1995	Feb CAHN

ISOSORBIDE MONONITRATE

TABLET;ORAL
ISOSORBIDE MONONITRATE

	AB		ANI PHARMS INC	20MG		A075147	001	Nov 27, 1998	Jan CAHN

ISRADIPINE

CAPSULE;ORAL
ISRADIPINE

		@	MIKAH PHARMA	2.5MG		A077169	001	Apr 24, 2006	Feb DISC
		@		5MG		A077169	002	Apr 24, 2006	Feb DISC
			WATSON LABS	2.5MG		A077317	001	Jan 05, 2006	Feb CTEC
		+		5MG		A077317	002	Jan 05, 2006	Feb CTEC

KETOCONAZOLE

TABLET;ORAL
NIZORAL

>A>	AB	+	JANSSEN PHARMS	200MG		N018533	001		Mar CAHN
>D>	AB	+	ORTHO MCNEIL JANSSEN	200MG		N018533	001		Mar CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC
ACUVAIL

	AT	+	ALLERGAN	0.45%		N022427	001	Jul 22, 2009	Jan CFTG

KETOROLAC TROMETHAMINE

		@	AKORN	0.45%		A203376	001	Feb 10, 2014	Feb DISC
	AT			0.45%		A203376	001	Feb 10, 2014	Jan NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL
LAMIVUDINE AND ZIDOVUDINE

	AB		HETERO LABS LTD V	150MG;300MG		A203259	001	Feb 03, 2014	Jan NEWA

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL
LANSOPRAZOLE

		@	ANI PHARMS INC	15MG		A078730	001	Oct 15, 2010	Jan CAHN
		@		30MG		A078730	002	Oct 15, 2010	Jan CAHN

LEVETIRACETAM

TABLET;ORAL
LEVETIRACETAM

	AB		VINTAGE PHARMS	250MG		A077319	001	Mar 20, 2009	Feb CAHN
	AB			500MG		A077319	002	Mar 20, 2009	Feb CAHN
	AB			750MG		A077319	003	Mar 20, 2009	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

	AB	VINTAGE PHARMS	500MG		A201464	001	May 25, 2012	Feb CAHN
	AB		750MG		A201464	002	May 25, 2012	Feb CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE
SOLUTION;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

	AA	L PERRIGO CO	2.5MG/5ML		A091263	001	Nov 07, 2011	Jan CAHN

LEVORPHANOL TARTRATE
TABLET;ORAL
LEVORPHANOL TARTRATE

		+ ROXANE	2MG		A074278	001	Mar 31, 2000	Feb CRLD

LIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

>A>	AP	AGILA SPECLTS	2%		A202242	001	Apr 11, 2014	Mar NEWA
>D>		LIDOPEN						
>D>	AP	MERIDIAN MEDCL TECHN	10%		N017549	001		Mar DISC
>A>		@	10%		N017549	001		Mar DISC
		XYLOCAINE PRESERVATIVE FREE						
>D>	AP	+ FRESENIUS KABI USA	10%		N016801	003		Mar CTEC
>A>		+	10%		N016801	003		Mar CTEC

JELLY;TOPICAL
ANESTACON

		@ DSM PHARMS INC	2%		A080429	001		Jan CAHN

SOLUTION;TOPICAL
LIDOCAINE HYDROCHLORIDE

	AT	IGI LABS INC	4%		A204494	001	Mar 12, 2014	Feb NEWA

SYSTEM;INTRADERMAL
ZINGO

>D>		@ POWDER PHARMS	0.5MG		N022114	001	Aug 16, 2007	Mar CMFD
>A>			0.5MG		N022114	001	Aug 16, 2007	Mar CMFD

LOTEPREDNOL ETABONATE
GEL;OPHTHALMIC
LOTEMAX

		+ BAUSCH AND LOMB INC	0.5%		N202872	001	Sep 28, 2012	Feb CAHN

LULICONAZOLE
CREAM;TOPICAL
LUZU

		+ MEDICIS	1%		N204153	001	Nov 14, 2013	Jan CRLD

MALATHION
LOTION;TOPICAL
MALATHION

>D>	AT	MYLAN PHARMS INC	0.5%		A078743	001	Mar 06, 2009	Mar DISC
>A>		@	0.5%		A078743	001	Mar 06, 2009	Mar DISC

MEDROXYPROGESTERONE ACETATE
TABLET;ORAL
MEDROXYPROGESTERONE ACETATE

>D>	BP	USL PHARMA	10MG		A088484	001	Jul 26, 1984	Mar DISC
>A>		@	10MG		A088484	001	Jul 26, 1984	Mar DISC

MEPERIDINE HYDROCHLORIDE
INJECTABLE;INJECTION
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	INTL MEDICATION	10MG/ML		A081309	001	Aug 30, 1993	Mar DISC
>A>		@	10MG/ML		A081309	001	Aug 30, 1993	Mar DISC

METFORMIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
GLUMETZA

>D>		+ SALIX PHARMS INC	1GM		N021748	002	Jun 03, 2005	Mar CAHN
		+	1GM		N021748	002	Jun 03, 2005	Feb CTEC
>D>			500MG		N021748	001	Jun 03, 2005	Mar CAHN
			500MG		N021748	001	Jun 03, 2005	Feb CTEC

TABLET, EXTENDED RELEASE;ORAL
GLUMETZA

>A>		+	SANTARUS INC	1GM	N021748	002	Jun 03, 2005	Mar CAHN
>A>				500MG	N021748	001	Jun 03, 2005	Mar CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB			TEVA PHARMS USA	500MG;EQ 15MG BASE	A091155	001	Mar 10, 2014	Feb NEWA
AB				850MG;EQ 15MG BASE	A091155	002	Mar 10, 2014	Feb NEWA

METHAZOLAMIDE

TABLET;ORAL
METHAZOLAMIDE

AB			ANI PHARMS INC	25MG	A040001	001	Jun 30, 1993	Jan CAHN
AB				50MG	A040001	002	Jun 30, 1993	Jan CAHN

METHIMAZOLE

TABLET;ORAL
METHIMAZOLE

AB			VINTAGE PHARMS	5MG	A202068	001	Mar 07, 2012	Feb CAHN
AB				10MG	A202068	002	Mar 07, 2012	Feb CAHN

METHSCOPOLAMINE BROMIDE

TABLET;ORAL
METHSCOPOLAMINE BROMIDE

AA			VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb CAHN
AA				5MG	A040624	002	Dec 28, 2006	Feb CAHN

METHYLERGONOVINE MALEATE

INJECTABLE;INJECTION
METHERGINE

AP		+	EDISON THERAPS LLC	0.2MG/ML	N006035	004		Feb CAHN

TABLET;ORAL
METHERGINE

AB		+	EDISON THERAPS LLC	0.2MG	N006035	003		Feb CAHN

METHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB			COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb NEWA
AB				10MG	A091159	002	Mar 12, 2014	Feb NEWA
AB				20MG	A091159	003	Mar 12, 2014	Feb NEWA

METRONIDAZOLE

GEL;VAGINAL
METRONIDAZOLE

>A>			VALEANT PHARM NORTH	1.3%	N205223	001	Mar 24, 2014	Mar NEWA

TABLET;ORAL
METRONIDAZOLE

>D>	AB		TEVA	500MG	A070044	001	Feb 08, 1985	Mar CAHN
	AB		UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014	Jan NEWA
	AB			500MG	A203458	002	Jan 22, 2014	Jan NEWA
>A>	AB		WATSON LABS INC	500MG	A070044	001	Feb 08, 1985	Mar CAHN

MILTEFOSINE

CAPSULE;ORAL
IMPAVIDO

>A>								
>A>			PALADIN THERAP	50MG	N204684	001	Mar 19, 2014	Mar NEWA

MIVACURIUM CHLORIDE

INJECTABLE;INJECTION
MIVACURIUM CHLORIDE

			@ AGILA SPECLTS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	Feb CAHN

MODAFINIL

TABLET;ORAL
MODAFINIL

AB			APOTEX INC	100MG	A077667	001	Feb 03, 2014	Jan NEWA
AB				200MG	A077667	002	Feb 03, 2014	Jan NEWA

MOMETASONE FUROATE

POWDER;INHALATION

ASMANEX TWISTHALER

>A>			MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008	Mar CAHN
>A>		+		0.22MG/INH	N021067	001	Mar 30, 2005	Mar CAHN
>D>			SCHERING	0.11MG/INH	N021067	002	Feb 01, 2008	Mar CAHN
>D>		+		0.22MG/INH	N021067	001	Mar 30, 2005	Mar CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AVINZA

>D>	AB2		KING PFIZER	30MG	N021260	001	Mar 20, 2002	Mar CAHN
>D>	AB2			45MG	N021260	005	Dec 18, 2008	Mar CAHN
>D>	AB2			60MG	N021260	002	Mar 20, 2002	Mar CAHN
>D>	AB2			75MG	N021260	006	Dec 18, 2008	Mar CAHN
>D>	AB2			90MG	N021260	003	Mar 20, 2002	Mar CAHN
>D>	AB2	+		120MG	N021260	004	Mar 20, 2002	Mar CAHN
>A>	AB2		KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002	Mar CAHN
>A>	AB2			45MG	N021260	005	Dec 18, 2008	Mar CAHN
>A>	AB2			60MG	N021260	002	Mar 20, 2002	Mar CAHN
>A>	AB2			75MG	N021260	006	Dec 18, 2008	Mar CAHN
>A>	AB2			90MG	N021260	003	Mar 20, 2002	Mar CAHN
>A>	AB2	+		120MG	N021260	004	Mar 20, 2002	Mar CAHN

SOLUTION;ORAL

MORPHINE SULFATE

	AA		CARACO	10MG/5ML	A201011	001	Feb 05, 2014	Jan NEWA
	AA			20MG/5ML	A201011	002	Feb 05, 2014	Jan NEWA

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMBEDA

>D>			ALPHARMA KING	20MG;0.8MG	N022321	001	Aug 13, 2009	Mar CAHN
>D>				30MG;1.2MG	N022321	002	Aug 13, 2009	Mar CAHN
>D>				50MG;2MG	N022321	003	Aug 13, 2009	Mar CAHN
>D>		+		60MG;2.4MG	N022321	004	Aug 13, 2009	Mar CAHN
>D>				80MG;3.2MG	N022321	005	Aug 13, 2009	Mar CAHN
>D>				100MG;4MG	N022321	006	Aug 13, 2009	Mar CAHN
>A>			ALPHARMA PHARMS	20MG;0.8MG	N022321	001	Aug 13, 2009	Mar CAHN
>A>				30MG;1.2MG	N022321	002	Aug 13, 2009	Mar CAHN
>A>				50MG;2MG	N022321	003	Aug 13, 2009	Mar CAHN
>A>		+		60MG;2.4MG	N022321	004	Aug 13, 2009	Mar CAHN
>A>				80MG;3.2MG	N022321	005	Aug 13, 2009	Mar CAHN
>A>				100MG;4MG	N022321	006	Aug 13, 2009	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

AVELOX

	AB	+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Feb CFTG

MOXIFLOXACIN HYDROCHLORIDE

	AB		AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014	Feb NEWA
	AB		DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Feb NEWA
	AB		TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014	Feb NEWA
>A>	AB		TORRENT PHARMS LTD	EQ 400MG BASE	A200160	001	Apr 03, 2014	Mar NEWA

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

>A>	AP		AGILA SPECLTS	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Mar NEWA
>A>	AP			EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Mar NEWA
	AP		ANTIBIOTICE	EQ 1GM BASE/VIAL	A090560	001	Oct 03, 2011	Jan CPOT
	AP			EQ 2GM BASE/VIAL	A090560	002	Oct 03, 2011	Jan CPOT
	AP		ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Feb CAHN
	AP			EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Feb CAHN
	AP			EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

	AP		MYLAN INSTITUTIONAL	0.4MG/ML	A204997	001	Mar 06, 2014	Feb NEWA

NAPROXEN

TABLET;ORAL

NAPROXEN

	@	DAVA PHARMS INC	250MG	A074410	001	Apr 28, 1995	Feb DISC
	@		375MG	A074410	002	Apr 28, 1995	Feb DISC
	@		500MG	A074410	003	Apr 28, 1995	Feb DISC

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

AB		APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Jan CAIN
AB			EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Jan CAIN
AB		SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan CAIN

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

AB		STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

>A>							
>A> AB		APOTEX INC	400MG	A205258	001	Apr 03, 2014	Mar NEWA
>A> AB		SANDOZ	400MG	A203411	001	Apr 03, 2014	Mar NEWA

VIRAMUNE XR

>D>	+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar CFTG
>A> AB	+		400MG	N201152	001	Mar 25, 2011	Mar CFTG

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

>A> AB		LUPIN LTD	1GM	A090446	001	Mar 20, 2014	Mar NEWA
>A> AB			500MG	A090860	001	Mar 20, 2014	Mar NEWA
>A> AB			750MG	A090892	001	Mar 20, 2014	Mar NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan CAHN
AB			20MG	A074540	001	Oct 28, 1996	Jan CAHN
AB			30MG	A074439	002	Dec 10, 1996	Jan CAHN
AB			30MG	A074540	002	Oct 28, 1996	Jan CAHN

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP		LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

>A> AB2		TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar NEWA
>A> AB2			60MG	A203126	002	Apr 03, 2014	Mar NEWA
>A> AB2			90MG	A203126	003	Apr 03, 2014	Mar NEWA

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

>A> AB		THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014	Mar NEWA

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

	@	ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002	Jan CAHN
AB			150MG	A075668	001	Sep 12, 2002	Jan CAHN
	@		300MG	A075461	002	Jul 08, 2002	Jan CAHN
AB			300MG	A075668	002	Sep 12, 2002	Jan CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

>D>	+	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar CFTG
>A> AB	+		1GM CONTAINS AT LEAST 900MG OF THE	N021654	001	Nov 10, 2004	Mar CFTG

		CAPSULE;ORAL						
		LOVAZA						
			ETHYL ESTERS OF OMEGA-3 FATTY ACIDS					
>A>		OMEGA-3-ACID ETHYL ESTERS						
>A>	AB	TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar	NEWA
		OMEPRAZOLE; SODIUM BICARBONATE						
		CAPSULE;ORAL						
		ZEGERID						
	AB	SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb	CAHN
	AB	+	40MG;1.1GM	N021849	002	Feb 27, 2006	Feb	CAHN
		FOR SUSPENSION;ORAL						
		ZEGERID						
	AB	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb	CAHN
	AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb	CAHN
		ONDANSETRON HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		ONDANSETRON HYDROCHLORIDE						
		@ LANNETT	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010	Jan	DISC
		TABLET;ORAL						
		ONDANSETRON HYDROCHLORIDE						
	AB	IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	Jan	NEWA
	AB		EQ 8MG BASE	A203761	002	Jan 23, 2014	Jan	NEWA
		OXACILLIN SODIUM						
		INJECTABLE;INJECTION						
		OXACILLIN SODIUM						
		@ ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995	Feb	CAHN
		@	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995	Feb	CAHN
		@	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995	Feb	CAHN
		@	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995	Feb	CAHN
		@	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995	Feb	CAHN
		OXALIPLATIN						
		INJECTABLE;IV (INFUSION)						
		OXALIPLATIN						
>A>	AP	SUN PHARMA GLOBAL	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Mar	NEWA
>A>	AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Mar	NEWA
		OXANDROLONE						
		TABLET;ORAL						
		OXANDRIN						
	AB	CREALTA PHARMS LLC	2.5MG	N013718	001		Jan	CAHN
	AB	+	10MG	N013718	002	Nov 05, 2001	Jan	CAHN
		OXCARBAZEPINE						
		TABLET;ORAL						
		OXCARBAZEPINE						
		@ ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jan	CAHN
		@	300MG	A078005	002	Dec 11, 2007	Jan	CAHN
		@	600MG	A078005	003	Dec 11, 2007	Jan	CAHN
		OXYBUTYNIN						
		FILM, EXTENDED RELEASE;TRANSDERMAL						
		OXYBUTYNIN						
	AB	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014	Feb	NEWA
		OXYTROL						
	AB	+ WATSON LABS (UTAH)	3.9MG/24HR	N021351	002	Feb 26, 2003	Feb	CFTG
		OXYTOCIN						
		SOLUTION;NASAL						
		SYNTOCINON						
		@ RETROPHIN INC	40USP UNITS/ML	N012285	001		Feb	CAHN

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

		@	MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009	Jan DISC
		@		90MG/VIAL	A078300	002	Mar 10, 2009	Jan DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

ZENPEP

>A>			APTALIS PHARMA US	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Mar NEWA

TABLET;ORAL

VIOKACE

>D>			APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar CAHN
>D>		+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar CAHN
>A>			FOREST RES INST INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar CAHN
>A>		+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar CAHN

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

>A>	AB		BANNER PHARMACAPS	1MCG	A202539	001	Mar 27, 2014	Mar NEWA
>A>	AB			2MCG	A202539	002	Mar 27, 2014	Mar NEWA
>A>	AB			4MCG	A202539	003	Mar 27, 2014	Mar NEWA

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL

PAXIL

		@	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
		@		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
		@		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
		@		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION;ORAL

PAXIL

	AB	+	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN

TABLET;ORAL

PAXIL

	AB		APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan CAHN
	AB			EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan CAHN
	AB			EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan CAHN
	AB	+		EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan CAHN
		@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

PAXIL CR

	AB		APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
	AB			EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
	AB	+		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PENICILLIN G POTASSIUM

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

	AP		ISTITUTO BIO ITA SPA	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb CAHN
	AP			20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb CAHN

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

	AB		ANI PHARMS INC	2MG	A078138	001	Nov 10, 2009	Jan CAHN
	AB			4MG	A078138	002	Nov 10, 2009	Jan CAHN
	AB			8MG	A078138	003	Nov 10, 2009	Jan CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

	AA		INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Feb NEWA
	AA			30MG	A202858	002	Feb 14, 2014	Feb NEWA
	AA			37.5MG	A202846	001	Feb 05, 2014	Jan NEWA

		TABLET;ORAL						
		PHENTERMINE HYDROCHLORIDE						
	AA	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Jan NEWA	
		PHENYTOIN SODIUM						
		CAPSULE;ORAL						
		EXTENDED PHENYTOIN SODIUM						
		@ ANI PHARMS INC	100MG EXTENDED	A089441	001	Dec 18, 1986	Jan CAHN	
		PROMPT PHENYTOIN SODIUM						
		@ ANI PHARMS INC	100MG PROMPT	A080259	001		Jan CAHN	
		PINDOLOL						
		TABLET;ORAL						
		PINDOLOL						
	AB	MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Feb CMFD	
	AB		10MG	A074063	002	Jan 27, 1994	Feb CMFD	
	AB	MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Feb CTEC	
	AB	+	10MG	A074019	002	Sep 03, 1992	Feb CTEC	
		PIOGLITAZONE HYDROCHLORIDE						
		TABLET;ORAL						
		PIOGLITAZONE HYDROCHLORIDE						
>A>	AB	LUPIN LTD	EQ 15MG BASE	A204133	001	Apr 07, 2014	Mar NEWA	
>A>	AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Mar NEWA	
>A>	AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Mar NEWA	
		PIPERACILLIN SODIUM						
		INJECTABLE;INJECTION						
		PIPERACILLIN						
	+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003	Feb CAHN	
	+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003	Feb CAHN	
	+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003	Feb CAHN	
	+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004	Feb CAHN	
		PIPERACILLIN SODIUM; TAZOBACTAM SODIUM						
		INJECTABLE;INJECTION						
		PIPERACILLIN AND TAZOBACTAM						
	AP	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb CAHN	
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb CAHN	
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb CAHN	
	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb CAHN	
		POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS						
		FOR SUSPENSION;ORAL						
		CO-LAV						
		@ VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428	001	Jan 28, 1992	Feb CAHN	
		GO-EVAC						
		@ VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433	001	Apr 28, 1992	Feb CAHN	
		POSACONAZOLE						
>A>		SOLUTION;IV (INFUSION)						
>A>		NOXAFIL						
>A>	+	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Mar NEWA	
		POTASSIUM CHLORIDE						
		INJECTABLE;INJECTION						
		POTASSIUM CHLORIDE						
>D>	AP	INTL MEDICATION	2MEQ/ML	A083163	001		Mar DISC	
>A>		@	2MEQ/ML	A083163	001		Mar DISC	
		PRAMIPEXOLE DIHYDROCHLORIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		MIRAPEX ER						
	AB	+ BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Jan CFTG	
	AB		0.75MG	N022421	002	Feb 19, 2010	Jan CFTG	
	AB		1.5MG	N022421	003	Feb 19, 2010	Jan CFTG	

		TABLET, EXTENDED RELEASE;ORAL					
		MIRAPEX ER					
	AB		2.25MG	N022421	006	Jun 17, 2011	Jan CFTG
	AB		3MG	N022421	004	Feb 19, 2010	Jan CFTG
	AB		3.75MG	N022421	007	Jun 17, 2011	Jan CFTG
	AB		4.5MG	N022421	005	Feb 19, 2010	Jan CFTG
		PRAMIPEXOLE DIHYDROCHLORIDE					
	AB	ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Jan NEWA
	AB		0.75MG	A202206	002	Feb 06, 2014	Jan NEWA
	AB		1.5MG	A202206	003	Feb 06, 2014	Jan NEWA
	AB		2.25MG	A202206	004	Feb 06, 2014	Jan NEWA
	AB		3MG	A202206	005	Feb 06, 2014	Jan NEWA
	AB		3.75MG	A202206	006	Feb 06, 2014	Jan NEWA
	AB		4.5MG	A202206	007	Feb 06, 2014	Jan NEWA
		PRAMLINTIDE ACETATE					
		INJECTABLE;SUBCUTANEOUS					
		SYMLIN					
		ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb CAHN
	+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb CAHN
	@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb CAHN
		PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM					
		SOLUTION/DROPS;OPHTHALMIC					
		SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE					
	AT +	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb CRLD
		VASOCIDIN					
	@	NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb DISC
		PRIMAQUINE PHOSPHATE					
		TABLET;ORAL					
		PRIMAQUINE					
	AB +	SANOFI AVENTIS US	EQ 15MG BASE	N008316	001		Jan CFTG
		PRIMAQUINE PHOSPHATE					
	AB	ALVOGEN INC	EQ 15MG BASE	A203924	001	Feb 03, 2014	Jan NEWA
	AB	BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Feb NEWA
		PROCAINAMIDE HYDROCHLORIDE					
		TABLET, EXTENDED RELEASE;ORAL					
		PROCAINAMIDE HYDROCHLORIDE					
		@ ANI PHARMS INC	1GM	A040111	001	Dec 13, 1996	Jan CAHN
		@	250MG	A088958	001	Dec 02, 1985	Jan CAHN
		@	500MG	A088959	001	Dec 02, 1985	Jan CAHN
>A>		@	500MG	A088974	001	Jul 22, 1985	Mar CAHN
		@	750MG	A089438	001	Mar 23, 1987	Jan CAHN
>D>		@ COPLEY PHARM	500MG	A088974	001	Jul 22, 1985	Mar CAHN
		PROPAFENONE HYDROCHLORIDE					
		TABLET;ORAL					
		PROPAFENONE HYDROCHLORIDE					
	AB	ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004	Jan CAHN
	AB		225MG	A076550	002	Apr 23, 2004	Jan CAHN
	AB		300MG	A076550	003	Apr 23, 2004	Jan CAHN
		PROPRANOLOL HYDROCHLORIDE					
		SOLUTION;ORAL					
		HEMANGEOL					
>A>	+	PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014	Mar NEWA
		TABLET;ORAL					
		INDERAL					
		@ WYETH PHARMS INC	40MG	N016418	002		Jan DISC
		@	60MG	N016418	009	Oct 18, 1982	Jan DISC
		@	80MG	N016418	004		Jan DISC
		PROPRANOLOL HYDROCHLORIDE					
		@ ANI PHARMS INC	90MG	A071977	001	Apr 06, 1988	Jan CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

	@	ANI PHARMS INC	50MG	A080215	001		Jan CAHN

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB	+	LILLY	60MG	N020815	001	Dec 09, 1997	Feb CFTG

RALOXIFENE HYDROCHLORIDE

AB		TEVA PHARMS USA	60MG	A078193	001	Mar 04, 2014	Feb NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

>A> AB		ACCORD HLTHCARE INC	1.25MG	A202392	001	Apr 15, 2014	Mar NEWA
>A> AB			2.5MG	A202392	002	Apr 15, 2014	Mar NEWA
>A> AB			5MG	A202392	003	Apr 15, 2014	Mar NEWA
>A> AB			10MG	A202392	004	Apr 15, 2014	Mar NEWA

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT;ORAL

ZANTAC 25

	@	GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004	Feb DISC

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB		ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Jan NEWA
AB			1MG	A090008	002	Jan 22, 2014	Jan NEWA
AB			2MG	A090008	003	Jan 22, 2014	Jan NEWA
AB		AUROBINDO PHARMA LTD	0.5MG	A203820	001	Jan 22, 2014	Jan NEWA
AB			1MG	A203820	002	Jan 22, 2014	Jan NEWA
AB			2MG	A203820	003	Jan 22, 2014	Jan NEWA
AB		MYLAN PHARMS INC	1MG	A090252	002	Jan 22, 2014	Jan NEWA
AB			2MG	A090252	003	Jan 22, 2014	Jan NEWA
AB		PADDOCK LLC	1MG	A201189	002	Jan 22, 2014	Jan NEWA
AB			2MG	A201189	003	Jan 22, 2014	Jan NEWA
AB		SANDOZ	1MG	A078555	002	Jan 22, 2014	Jan NEWA
AB			2MG	A078555	003	Jan 22, 2014	Jan NEWA

RIFABUTIN

CAPSULE;ORAL

MYCOBUTIN

AB	+	PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992	Feb CFTG

RIFABUTIN

AB		LUPIN LTD	150MG	A090033	001	Feb 24, 2014	Feb NEWA

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA		ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009	Jan CAHN

TABLET;ORAL

RISPERIDONE

AB		CARACO	0.25MG	A078036	001	Mar 10, 2014	Feb NEWA
AB			0.5MG	A078036	002	Mar 10, 2014	Feb NEWA
AB			1MG	A078036	003	Mar 10, 2014	Feb NEWA
AB			2MG	A078036	004	Mar 10, 2014	Feb NEWA
AB			3MG	A078036	005	Mar 10, 2014	Feb NEWA
AB			4MG	A078036	006	Mar 10, 2014	Feb NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB		MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014	Jan NEWA
AB			EQ 10MG BASE	A203147	002	Feb 11, 2014	Jan NEWA

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

	+	JANSSEN RES AND DEV	EQ 150MG BASE	N205123	001	Nov 22, 2013	Feb	CAIN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

>A>	AP	UCSF RODIOPHARM	10-200mCi/ML	A204437	001	Mar 13, 2014	Mar	NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>A>	AA	EPIC PHARMA LLC	453.6GM/BOT	A202333	001	Mar 19, 2014	Mar	NEWA

SOLIFENACIN SUCCINATE

TABLET;ORAL

>A>		SOLIFENACIN SUCCINATE						
>A>	AB	TEVA PHARMS USA	5MG	A091464	001	Apr 02, 2014	Mar	NEWA
>A>	AB		10MG	A091464	002	Apr 02, 2014	Mar	NEWA
		VESICARE						
>D>		ASTELLAS	5MG	N021518	001	Nov 19, 2004	Mar	CFTG
>A>	AB		5MG	N021518	001	Nov 19, 2004	Mar	CFTG
>D>		+	10MG	N021518	002	Nov 19, 2004	Mar	CFTG
>A>	AB	+	10MG	N021518	002	Nov 19, 2004	Mar	CFTG

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

ACCRETROPIN

		@ EMERGENT	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008	Feb	CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

	AB	ORION CORP ORION	25MG	A202187	001	Mar 06, 2014	Feb	NEWA
	AB		50MG	A202187	002	Mar 06, 2014	Feb	NEWA
	AB		100MG	A202187	003	Mar 06, 2014	Feb	NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

>A>	AP	AGILA SPECLTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Mar	NEWA
	AB	DR REDDYS LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090495	001	Jan 29, 2014	Jan	NEWA

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

	AB	MYLAN PHARMS INC	EQ 12.5MG BASE	A201275	001	Jan 30, 2014	Jan	NEWA
	AB		EQ 25MG BASE	A201275	002	Jan 30, 2014	Jan	NEWA
	AB		EQ 37.5MG BASE	A201275	003	Jan 30, 2014	Jan	NEWA
	AB		EQ 50MG BASE	A201275	004	Jan 30, 2014	Jan	NEWA
		SUTENT						
	AB	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Jan	CFTG
	AB		EQ 25MG BASE	N021938	002	Jan 26, 2006	Jan	CFTG
	AB		EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Jan	CFTG
	AB	+	EQ 50MG BASE	N021938	003	Jan 26, 2006	Jan	CFTG

TASIMELTEON

CAPSULE;ORAL

HETLIOZ

	+	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014	Jan	NEWA

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

	AB	SUN PHARMA GLOBAL	5MG	A201742	001	Feb 12, 2014	Feb	NEWA
	AB		20MG	A201742	002	Feb 12, 2014	Feb	NEWA
	AB		100MG	A201742	003	Feb 12, 2014	Feb	NEWA
	AB		140MG	A201742	004	Feb 12, 2014	Feb	NEWA

CAPSULE;ORAL
TEMOZOLOMIDE

	AB		180MG	A201742	005	Feb 12, 2014	Feb NEWA
	AB		250MG	A201742	006	Feb 12, 2014	Feb NEWA

TESTOSTERONE UNDECANOATE

INJECTABLE;INTRAMUSCULAR
AVEED

>A>		+ ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 04, 2014	Mar NEWA

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

		@ CARACO	300MG	A087400	002	Jan 11, 1983	Jan DISC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE;ORAL
THIORIDAZINE HYDROCHLORIDE

		@ ANI PHARMS INC	100MG/ML	A089603	001	Nov 09, 1987	Feb CAHN

TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

		@ ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983	Feb CAHN
		@	10MG	A088493	001	May 17, 1985	Feb CAHN
		@	15MG	A088271	001	Apr 14, 1983	Feb CAHN
		@	25MG	A088272	001	Apr 14, 1983	Feb CAHN
		@	50MG	A088194	001	Apr 14, 1983	Feb CAHN
		@	100MG	A088273	001	Oct 03, 1983	Feb CAHN
		@	100MG	A088456	001	May 17, 1985	Feb CAHN

TOPIRAMATE

CAPSULE, DELAYED RELEASE;ORAL
QUDEXY XR

>A>		UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Mar NEWA
>A>			50MG	N205122	002	Mar 11, 2014	Mar NEWA
>A>			100MG	N205122	003	Mar 11, 2014	Mar NEWA
>A>			150MG	N205122	004	Mar 11, 2014	Mar NEWA
>A>		+	200MG	N205122	005	Mar 11, 2014	Mar NEWA

TRAMADOL HYDROCHLORIDE

TABLET;ORAL
TRAMADOL HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	50MG	A203494	001	Mar 31, 2014	Mar NEWA

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

	AP	ACIC FINE CHEMS	100MG/ML	A202436	001	Feb 11, 2014	Jan NEWA

TABLET;ORAL
TRANEXAMIC ACID

	AB	APOTEX INC	650 MG	A202286	001	Jan 27, 2014	Jan NEWA

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC
TRAVOPROST

		+ PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb CRLD

TRETINOIN

GEL;TOPICAL
RETIN-A-MICRO

		+ VALEANT INTL	0.08%	N020475	003	Jan 28, 2014	Jan NEWA

SOLUTION;TOPICAL
RETIN-A

		+ VALEANT INTL	0.05%	N016921	001		Feb CTEC

TRETINOIN

		@ WOCKHARDT	0.05%	A075260	001	Jan 25, 1999	Feb DISC

TRIAMCINOLONE ACETONIDE

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT		TARO	0.1%	A089129	001	Aug 14, 1986	Mar DISC
>A>		@		0.1%	A089129	001	Aug 14, 1986	Mar DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

>A>	AB		APOTEX INC	EQ 1GM BASE	A090500	002	Apr 04, 2014	Mar NEWA
>A>	AB			EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar NEWA
	AB		CIPLA LTD	EQ 1GM BASE	A077135	002	May 24, 2010	Jan CAHN
	AB			EQ 500MG BASE	A077135	001	May 24, 2010	Jan CAHN

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

	AA		ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Jan CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

	AP		AGILA SPECLTS	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Feb CAHN

WARFARIN SODIUM

INJECTABLE;INJECTION

>D>			COUMADIN					
>D>		+	BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995	Mar DISC
>A>		@		5MG/VIAL	N009218	024	Feb 07, 1995	Mar DISC

TABLET;ORAL

>D>			COUMADIN					
>D>	AB		BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Mar DISC
>A>		@		1MG	N009218	022	Mar 01, 1990	Mar DISC
>D>	AB			2MG	N009218	013		Mar DISC
>A>		@		2MG	N009218	013		Mar DISC
>D>	AB			2.5MG	N009218	018		Mar DISC
>A>		@		2.5MG	N009218	018		Mar DISC
>D>	AB			3MG	N009218	025	Nov 18, 1996	Mar DISC
>A>		@		3MG	N009218	025	Nov 18, 1996	Mar DISC
>D>	AB			4MG	N009218	023	Aug 24, 1993	Mar DISC
>A>		@		4MG	N009218	023	Aug 24, 1993	Mar DISC
>D>	AB			5MG	N009218	007		Mar DISC
>A>		@		5MG	N009218	007		Mar DISC
>D>	AB			6MG	N009218	026	Nov 18, 1996	Mar DISC
>A>		@		6MG	N009218	026	Nov 18, 1996	Mar DISC
>D>	AB			7.5MG	N009218	016		Mar DISC
>A>		@		7.5MG	N009218	016		Mar DISC
>D>	AB	+		10MG	N009218	005		Mar DISC
>A>		@		10MG	N009218	005		Mar DISC

ZICONOTIDE ACETATE

INJECTABLE;INTRATHECAL

PRIALT

		@	JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Feb CAIN

ZIDOVUDINE

INJECTABLE;INJECTION

ZIDOVUDINE

>D>	AP		LIAONING CHENGDA	10MG/ML	A204538	001	Nov 26, 2013	Mar DISC
>A>		@		10MG/ML	A204538	001	Nov 26, 2013	Mar DISC

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

>A>	AB		INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar NEWA
>A>	AB			5MG	A204284	002	Apr 09, 2014	Mar NEWA
	AB		TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb NEWA
	AB			5MG	A090861	002	Mar 04, 2014	Feb NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	ANI PHARMS INC	25MG	A077639	001	Dec 22, 2005		Jan CAHN
@		25MG	A077641	003	Dec 22, 2005		Jan CAHN
AB		50MG	A077639	002	Dec 22, 2005		Jan CAHN
@		50MG	A077641	002	Dec 22, 2005		Jan CAHN
AB		100MG	A077639	003	Dec 22, 2005		Jan CAHN
@		100MG	A077641	001	Dec 22, 2005		Jan CAHN
@	SANDOZ	25MG	A077644	001	Dec 22, 2005		Feb DISC
@		50MG	A077644	002	Dec 22, 2005		Feb DISC
@		100MG	A077644	003	Dec 22, 2005		Feb DISC

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL							
DRIXORAL PLUS							
@	SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987	Feb	DISC

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL							
CETIRIZINE HYDROCHLORIDE ALLERGY							
	IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014	Feb	NEWA
		10MG	A202277	004	Mar 11, 2014	Feb	NEWA
CETIRIZINE HYDROCHLORIDE HIVES							
	IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014	Feb	NEWA
		10MG	A202277	003	Mar 11, 2014	Feb	NEWA
TABLET, CHEWABLE;ORAL							
CETIRIZINE HYDROCHLORIDE ALLERGY							
@	CARACO	5MG	A077631	004	Jan 11, 2008	Feb	DISC
@		10MG	A077631	003	Jan 11, 2008	Feb	DISC
CETIRIZINE HYDROCHLORIDE HIVES RELIEF							
@	CARACO	5MG	A077631	001	Jan 11, 2008	Feb	DISC
@		10MG	A077631	002	Jan 11, 2008	Feb	DISC

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL							
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE							
+	AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Jan	CRLD
DISOPHROL							
@	SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982	Jan	DISC
DRIXORAL							
@	SCHERING PLOUGH	6MG;120MG	N013483	003	Sep 13, 1982	Jan	DISC

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL							
ALEVE PM							
+	BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014	Jan	NEWA

IBUPROFEN

TABLET;ORAL							
IBUPROFEN							
>A>	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Mar	NEWA

MINOXIDIL

AEROSOL, FOAM;TOPICAL							
WOMEN'S ROGAINE							
+	JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014	Feb	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2014

NO MARCH 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MARCH 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR								
N 204031	001	>A>	6488962	Jun 20, 2020	DP		>A> NP	Mar 03, 2017
		>A>	7976870	Jun 01, 2027	U-1498			
		>A>	8372432	Mar 11, 2029	DP U-1499			
		>A>	8377453	Nov 19, 2029	DP U-1499			
		>A>	8394408	Mar 11, 2029	DP			
		>A>	8597681	Dec 21, 2030	DP			
		>A>	8658631	May 16, 2032	DP			
		>A>	8668929	Mar 11, 2029	U-1499			
ACETYLCYSTEINE - ACETADOTE								
N 021539	001		8653061	Aug 24, 2025	U-1373			
ACYCLOVIR; HYDROCORTISONE - XERESE								
N 022436	001		6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
			6514980	Jan 24, 2019	DP U-1484			
			7223387	May 13, 2023	DP U-1006			
			7223387	May 13, 2023	DP U-1484			
			RE39264	Aug 02, 2016	DP U-1006			
			RE39264	Aug 02, 2016	DP U-1484			
ADENOSINE - ADENOSINE								
A 077425	001						>A> PC	Mar 22, 2014
ALCAFTADINE - LASTACAFT								
N 022134	001	>A>	8664215	Oct 05, 2029	U-1493			
ALISKIREN HEMIFUMARATE - TEKTURNA								
N 021985	001		8617595	Feb 19, 2026	DP			
ALISKIREN HEMIFUMARATE - TEKTURNA								
N 021985	002		8617595	Feb 19, 2026	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO								
N 022545	001		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO								
N 022545	002		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO								
N 022545	003		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO								
N 022545	004		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	001		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	002		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	003		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	004		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N 200045	005		8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N 022107	001		8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N 022107	002		8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N 022107	003		8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N 022107	004		8618172	Jul 13, 2028	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI								
N 022426	001		8637079	Jan 23, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI								
N 022426	002		8637079	Jan 23, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 003		8637079	Jan 23, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 004		8637079	Jan 23, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 005		8637079	Jan 23, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 006		8637079	Jan 23, 2029	DP			
ALVIMOPAN - ENTEREG							
N 021775 001		8645160	Jun 18, 2029	U-1485			
APIXABAN - ELIQUIS							
N 202155 001	>A>	6413980	Dec 22, 2019	DS DP U-1200		>A> I-681	Mar 03, 2017
	>A>	6413980	Dec 22, 2019	DS DP U-1501			
	>A>	6967208	Feb 03, 2023	DS DP U-1167			
	>A>	6967208	Feb 03, 2023	DS DP U-1200			
	>A>	6967208	Feb 03, 2023	DS DP U-1323			
	>A>	6967208	Feb 03, 2023	DS DP U-1501			
	>A>	6967208	Feb 03, 2023	DS DP U-1502			
APREMILAST - OTEZLA							
N 205437 001						>A> NCE	Mar 21, 2019
APREMILAST - OTEZLA							
N 205437 002						>A> NCE	Mar 21, 2019
APREMILAST - OTEZLA							
N 205437 003						>A> NCE	Mar 21, 2019
ARIPIPRAZOLE - ABILIFY							
N 021436 001		8642600	Jan 28, 2022	U-1492			
		8642600*PED	Jul 28, 2022				
		8642760	Sep 25, 2022	DS			
		8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY							
N 021436 002		8642600	Jan 28, 2022	U-1492			
		8642600*PED	Jul 28, 2022				
		8642760	Sep 25, 2022	DS			
		8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY							
N 021436 003		8642600	Jan 28, 2022	U-1492			
		8642600*PED	Jul 28, 2022				
		8642760	Sep 25, 2022	DS			
		8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY							
N 021436 004		8642600	Jan 28, 2022	U-1492			
		8642600*PED	Jul 28, 2022				
		8642760	Sep 25, 2022	DS			
		8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY							
N 021436 005		8642600	Jan 28, 2022	U-1492			
		8642600*PED	Jul 28, 2022				
		8642760	Sep 25, 2022	DS			
		8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY							
N 021436 006		8642600	Jan 28, 2022	U-1492			
		8642600*PED	Jul 28, 2022				
		8642760	Sep 25, 2022	DS			
		8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY							
N 021713 001		8642600	Jan 28, 2022	U-1492			
		8642600*PED	Jul 28, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY								
N 021729	002		8642600	Jan 28, 2022	U-1492			
			8642600*PED	Jul 28, 2022				
			8642760	Sep 25, 2022	DS			
			8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY								
N 021729	003		8642600	Jan 28, 2022	U-1492			
			8642600*PED	Jul 28, 2022				
			8642760	Sep 25, 2022	DS			
			8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY								
N 021729	004		8642600	Jan 28, 2022	U-1492			
			8642600*PED	Jul 28, 2022				
			8642760	Sep 25, 2022	DS			
			8642760*PED	Mar 25, 2023				
ARIPIPRAZOLE - ABILIFY								
N 021729	005		8642600	Jan 28, 2022	U-1492			
			8642600*PED	Jul 28, 2022				
			8642760	Sep 25, 2022	DS			
			8642760*PED	Mar 25, 2023				
BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE								
N 022247	001						>A> NP	Oct 03, 2016
BEDAQUILINE FUMARATE - SIRTURO								
N 204384	001	>A>	8546428	Mar 19, 2029	DS DP U-1321			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA								
N 050819	001		8663699	Jun 03, 2029	U-124			
BIMATOPROST - LATISSE								
N 022369	001		8263054	Jan 15, 2023	U-1277			
			8632760	Jan 15, 2023	U-1487			
BORTEZOMIB - VELCADE								
N 021602	001						ODE	Jun 20, 2015
BROMFENAC SODIUM - PROLENSA								
N 203168	001	>A>	8669290	Jan 16, 2024	DP			
BROMOCRIPTINE MESYLATE - CYCLOSET								
N 020866	001		8613947	Apr 30, 2032	DP U-976			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT								
N 021929	001		8616196	Apr 07, 2029	DP			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT								
N 021929	002		8616196	Apr 07, 2029	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	001	>A>	8658198	Dec 03, 2027	DP U-1494			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	002	>A>	8658198	Dec 03, 2027	DP U-1494			
CABAZITAXEL - JEVTANA KIT								
N 201023	001		5847170	Mar 26, 2021	DS DP			
CLEVIDIPINE - CLEVIPREX								
N 022156	001		8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX								
N 022156	002		8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX								
N 022156	003		5739152	Apr 14, 2015	DP U-893			
			5856346	Jan 05, 2021	DS DP U-893			
			8658676	Oct 10, 2031	DP			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD								
N 203100	001		8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
CYANOCOBALAMIN - NASCOBAL								
N 021642	001	>A>	8003353	Jun 11, 2024	U-817			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYCLOSPORINE - RESTASIS							
N 050790 001		8633162	Aug 27, 2024	U-1479			
		8642556	Aug 27, 2024	DP			
		8648048	Aug 27, 2024	U-1483			
	>A>	8685930	Aug 27, 2024	DP			
DABRAFENIB MESYLATE - TAFINLAR							
N 202806 001						I-678	Jan 08, 2017
						ODE	Jan 09, 2021
DABRAFENIB MESYLATE - TAFINLAR							
N 202806 002						I-678	Jan 08, 2017
						ODE	Jan 09, 2021
DALFAMPRIDINE - AMPYRA							
N 022250 001	>A>	8663685	Jan 18, 2025	U-1030			
DAPAGLIFLOZIN - FARXIGA							
N 202293 001						NCE	Jan 08, 2019
DAPAGLIFLOZIN - FARXIGA							
N 202293 002						NCE	Jan 08, 2019
DARUNAVIR ETHANOLATE - PREZISTA							
N 021976 001		8597876	Jun 23, 2019	U-1305			
		8597876*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA							
N 021976 002		8597876	Jun 23, 2019	U-1305			
		8597876*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA							
N 021976 003		8597876	Jun 23, 2019	U-1305			
		8597876*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA							
N 021976 004		8597876	Jun 23, 2019	U-1305			
		8597876*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA							
N 021976 005		8597876	Jun 23, 2019	U-1305			
		8597876*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA							
N 021976 006		8597876	Jun 23, 2019	U-1305			
		8597876*PED	Dec 23, 2019				
DASATINIB - SPRYCEL							
N 021986 001	>A>	8680103	Feb 04, 2025	DP			
DASATINIB - SPRYCEL							
N 021986 002	>A>	8680103	Feb 04, 2025	DP			
DASATINIB - SPRYCEL							
N 021986 003	>A>	8680103	Feb 04, 2025	DP			
DASATINIB - SPRYCEL							
N 021986 004	>A>	8680103	Feb 04, 2025	DP			
DASATINIB - SPRYCEL							
N 021986 005	>A>	8680103	Feb 04, 2025	DP			
DASATINIB - SPRYCEL							
N 021986 006	>A>	8680103	Feb 04, 2025	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX							
N 021038 001						M-61	Jun 17, 2016
						PED	Dec 17, 2016
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX							
N 021038 002		8648106	Jan 04, 2032	DP		M-61	Jun 17, 2016
		8648106*PED	Jul 04, 2032			PED	Dec 17, 2016
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX							
N 021038 003		8648106	Jan 04, 2032	DP		M-61	Jun 17, 2016
		8648106*PED	Jul 04, 2032			PED	Dec 17, 2016
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE							
A 078992 003						PC	May 18, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC - ZORVOLEX						
N 204592 001 >A>	8679544	Apr 23, 2030	DP			
DICLOFENAC - ZORVOLEX						
N 204592 002 >A>	8679544	Apr 23, 2030	DP			
DICLOFENAC EPOLAMINE - FLECTOR						
N 021234 001	5607690	Apr 13, 2019	DP			
DICLOFENAC POTASSIUM - ZIPSOR						
N 022202 001	6287594	Jan 15, 2019	DP			
	8623920	Feb 24, 2029	U-1482			
DICLOFENAC SODIUM - PENNSAID						
N 204623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM						
N 205352 001					NC	Jan 17, 2017
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ						
N 022532 001	8617597	Feb 08, 2030	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL						
N 022574 001	8617597	Feb 08, 2030	DP			
DROXIDOPA - NORTHERA						
N 203202 001					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
DROXIDOPA - NORTHERA						
N 203202 002					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
DROXIDOPA - NORTHERA						
N 203202 003					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090745 001					>A> PC	Jun 09, 2014
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090745 002					>A> PC	Jun 09, 2014
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090745 003					>A> PC	Jun 09, 2014
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090774 001					>A> PC	Jun 09, 2014
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090774 002					>A> PC	Jun 09, 2014
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090774 003					>A> PC	Jun 09, 2014
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090778 001					>A> PC	Jun 09, 2014
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090778 002					>A> PC	Jun 09, 2014
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090778 003					>A> PC	Jun 09, 2014
ENTECAVIR - BARACLUDE						
N 021797 001					>A> NPP	Mar 20, 2017
					>A> PED	Sep 20, 2017
ENTECAVIR - BARACLUDE						
N 021797 002					>A> NPP	Mar 20, 2017
					>A> PED	Sep 20, 2017
ENTECAVIR - BARACLUDE						
N 021798 001					>A> NPP	Mar 20, 2017
					>A> PED	Sep 20, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE SODIUM - NEXIUM IV							
N 021689 001	>A>	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	>A>	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	>A>	5877192*PED	Nov 27, 2014				
	>A>	6143771	May 27, 2014	DP U-643			
	>A>	6143771	May 27, 2014	DP U-1495			
ESOMEPRAZOLE SODIUM - NEXIUM IV							
N 021689 002	>A>	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	>A>	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	>A>	5877192*PED	Nov 27, 2014				
	>A>	6143771	May 27, 2014	DP U-643			
	>A>	6143771	May 27, 2014	DP U-1495			
EVEROLIMUS - AFINITOR DISPERZ							
N 203985 001	>A>	8617598	Sep 27, 2022	DP			
EVEROLIMUS - AFINITOR DISPERZ							
N 203985 002	>A>	8617598	Sep 27, 2022	DP			
EVEROLIMUS - AFINITOR DISPERZ							
N 203985 003	>A>	8617598	Sep 27, 2022	DP			
EZETIMIBE - ZETIA							
N 021445 001		7612058	Oct 30, 2025	U-1027			
		7612058	Oct 30, 2025	U-1173			
		7612058*PED	Apr 30, 2026				
FENTANYL - SUBSYS							
N 202788 001		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS							
N 202788 002		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS							
N 202788 003		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS							
N 202788 004		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS							
N 202788 005		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS							
N 202788 006		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
FENTANYL - SUBSYS							
N 202788 007		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
FLORBETABEN F-18 - NEURACEQ							
N 204677 001	>A>	7907135	Mar 18, 2029	DS DP U-1497		>A> NCE	Mar 21, 2019
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA							
N 021112 001		8653053	Oct 25, 2022	DP			
FLUOCINONIDE - FLUOCINONIDE							
A 090256 001						PC	Jul 13, 2014
FLUTEMETAMOL F-18 - VIZAMYL							
N 203137 001	>A>	7270800	Jan 24, 2023	DS DP U-336		>A> NCE	Oct 25, 2018
	>A>	7351401	Jan 24, 2023	DS DP U-336			
FLUTEMETAMOL F-18 - VIZAMYL							
N 203137 002	>A>	7270800	Jan 24, 2023	DS DP U-336		>A> NCE	Oct 25, 2018
	>A>	7351401	Jan 24, 2023	DS DP U-336			
FLUTICASONE FUROATE - VERAMYST							
N 022051 001		8147461	Oct 15, 2028	DP			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275 001						NP	May 10, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN ENACARBIL - HORIZANT							
N 022399 001						ODE	Jun 06, 2019
GABAPENTIN ENACARBIL - HORIZANT							
N 022399 002						ODE	Jun 06, 2019
GLATIRAMER ACETATE - COPAXONE							
N 020622 003		6054430	May 24, 2014	DS		>A> NP	Jan 28, 2017
		6342476	May 24, 2014	U-441			
		6362161	May 24, 2014	DS			
		7199098	May 24, 2014	DS			
		8232250	Aug 19, 2030	U-441			
		8367605	May 24, 2014	DS			
		8399413	Sep 06, 2030	U-441			
GLYCEROL PHENYLBUTYRATE - RAVICTI							
N 203284 001		8642012	Sep 22, 2030	U-1383			
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT							
N 022555 001		7348361	Nov 06, 2020	DP U-1087			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880 001		6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880 002		6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880 003		6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880 004		6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880 005		6228398	Nov 01, 2019	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880 006		6228398	Nov 01, 2019	DP			
IBRUTINIB - IMBRUVICA							
N 205552 001		8476284	Dec 28, 2026	U-1456		I-680	Feb 12, 2017
		8476284	Dec 28, 2026	U-1491		ODE	Feb 12, 2021
		8497277	Dec 28, 2026	U-1456			
		8497277	Dec 28, 2026	U-1491			
ICOSAPENT ETHYL - VASCEPA							
N 202057 001						NP	Jul 26, 2015
IMATINIB MESYLATE - GLEEVEC							
N 021335 001		RE43932	Jan 16, 2019	DS DP			
		RE43932*PED	Jul 16, 2019				
IMATINIB MESYLATE - GLEEVEC							
N 021335 002		RE43932	Jan 16, 2019	DS DP			
		RE43932*PED	Jul 16, 2019				
INDOMETHACIN - TIVORBEX							
N 204768 001						NP	Feb 24, 2017
INDOMETHACIN - TIVORBEX							
N 204768 002						NP	Feb 24, 2017
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH							
N 020986 005		6899699	Jan 02, 2022	DP			
		7686786	Aug 03, 2026	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH							
N 021536 005		6899699	Jan 02, 2022	DP			
		7686786	Aug 03, 2026	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR							
N 021081 002	>A>	8679069	Apr 12, 2025	DP			
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR							
N 021629 003	>A>	8679069	Apr 12, 2025	DP			
IOFLUPANE I-123 - DATSCAN							
N 022454 001	>A>	5310912	Feb 25, 2015	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
KETOROLAC TROMETHAMINE - ACULAR LS							
N 021528 001		8648107	May 28, 2024	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115 001		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115 002		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115 003		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115 004		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115 005		8637512	Jun 14, 2028	DP			
LAMOTRIGINE - LAMICTAL XR							
N 022115 006		8637512	Jun 14, 2028	DP			
LENALIDOMIDE - REVLIMID							
N 021880 001		8626531	Oct 23, 2020	U-1210			
		8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 002		8626531	Oct 23, 2020	U-1210			
		8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 003		8626531	Oct 23, 2020	U-1210			
		8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 004		8626531	Oct 23, 2020	U-1210			
		8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 005		8626531	Oct 23, 2020	U-1210			
		8648095	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 006		8626531	Oct 23, 2020	U-1210			
		8648095	May 15, 2023	U-1216			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281 001	>A>	8673927	Aug 23, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281 002	>A>	8673927	Aug 23, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281 003	>A>	8673927	Aug 23, 2027	U-1503			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 001		8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 002		8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 003		8618135	Mar 07, 2025	U-1316			
LOXAPINE - ADASUVE							
N 022549 001		7052679	Oct 26, 2021	DP			
		7537009	Oct 28, 2024	DP			
		8074644	Jul 25, 2022	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024 001	>A>	8668931	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024 002	>A>	8668931	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678 001		8628799	Jul 13, 2025	DP		M-134	May 24, 2016
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678 002						M-134	May 24, 2016
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678 003						M-134	May 24, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE - DAYTRANA							
N 021514 001		8632802	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 002		8632802	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 003		8632802	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 004		8632802	Oct 07, 2025	DP			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 001		8629179	Jul 31, 2017	DP			
		8629179*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 002		8629179	Jul 31, 2017	DP			
		8629179*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 003		8629179	Jul 31, 2017	DP			
		8629179*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 004		8629179	Jul 31, 2017	DP			
		8629179*PED	Jan 31, 2018				
METRONIDAZOLE - METRONIDAZOLE							
N 205223 001						>A> NP	Mar 24, 2017
MILTEFOSINE - IMPAVIDO							
N 204684 001						>A> NCE	Mar 19, 2019
						>A> ODE	Mar 19, 2021
MINOXIDIL - WOMEN'S ROGAINE							
N 021812 002						NP	Feb 28, 2017
MYCOPHENOLIC ACID - MYCOPHENOLIC ACID							
A 091248 001						PC	Jul 07, 2014
NIACIN - NIACIN							
A 076250 001						PC	Mar 19, 2014
NIACIN - NIACIN							
A 076378 001						PC	Mar 19, 2014
NIACIN - NIACIN							
A 076378 002						PC	Mar 19, 2014
NICOTINE - NICODERM CQ							
N 020165 004	>A>	8663680	Feb 13, 2020	DP			
NICOTINE - NICODERM CQ							
N 020165 005	>A>	8663680	Feb 13, 2020	DP			
NICOTINE - NICODERM CQ							
N 020165 006	>A>	8663680	Feb 13, 2020	DP			
NITRIC OXIDE - INOMAX							
N 020845 002						M-132	Dec 21, 2013
						PED	Jun 21, 2014
NITRIC OXIDE - INOMAX							
N 020845 003						M-132	Dec 21, 2013
						PED	Jun 21, 2014
OSPEMIFENE - OSPHENA							
N 203505 001		8642079	Mar 01, 2028	DP			
OXYCODONE HYDROCHLORIDE - OXECTA							
N 202080 001		8637540	Nov 26, 2023	DP			
OXYCODONE HYDROCHLORIDE - OXECTA							
N 202080 002		8637540	Nov 26, 2023	DP			
PAROXETINE MESYLATE - BRISDELLE							
N 204516 001		8658663	Apr 06, 2029	DS DP U-904			
PERFLUTREN - DEFINITY							
N 021064 001		8658205	Apr 20, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POMALIDOMIDE - POMALYST						
N 204026 001	8626531	Oct 23, 2020	U-1361			
>A>	8673939	May 15, 2023	U-1360			
POMALIDOMIDE - POMALYST						
N 204026 002	8626531	Oct 23, 2020	U-1361			
>A>	8673939	May 15, 2023	U-1360			
POMALIDOMIDE - POMALYST						
N 204026 003	8626531	Oct 23, 2020	U-1361			
>A>	8673939	May 15, 2023	U-1360			
POMALIDOMIDE - POMALYST						
N 204026 004	8626531	Oct 23, 2020	U-1361			
>A>	8673939	May 15, 2023	U-1360			
POSACONAZOLE - NOXAFIL						
N 205596 001 >A>	8410077	Mar 13, 2029	DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 001 >A>	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 002 >A>	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 003 >A>	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 004 >A>	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 005 >A>	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 006 >A>	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 007 >A>	8679533	Sep 08, 2029	DP U-219			
PROPRANOLOL HYDROCHLORIDE - HEMANGEOL						
N 205410 001 >A>	8338489	Oct 16, 2028	U-1496		>A> NP	Mar 14, 2017
					>A> ODE	Mar 14, 2021
RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE						
A 078193 001					>A> PC	Sep 24, 2014
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
REGORAFENIB - STIVARGA						
N 203085 001	8637553	Jul 08, 2029	DS DP			
RIFAXIMIN - XIFAXAN						
N 021361 001	8642573	Oct 02, 2029	U-1481			
RIFAXIMIN - XIFAXAN						
N 022554 001	8642573	Oct 02, 2029	U-1481			
ROFLUMILAST - DALIRESP						
N 022522 001	8618142	Mar 08, 2024	DP			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 001					M-134	May 24, 2016
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 002					M-134	May 24, 2016
SILDENAFIL CITRATE - REVATIO						
N 021845 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
SILDENAFIL CITRATE - REVATIO						
N 022473 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SILDENAFIL CITRATE - REVATIO								
N 203109	001						D-137	Jan 31, 2017
							M-133	Jan 31, 2017
SIROLIMUS - SIROLIMUS								
A 201676	003						PC	Jul 15, 2014
SOFOSBUVIR - SOVALDI								
N 204671	001		8618076	Dec 11, 2030	DS DP U-1470			
			8633309	Mar 26, 2029	DS DP U-1470			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO								
N 021148	008	>A>	8672898	Jan 02, 2022	DP			
		>A>	8684969	Oct 20, 2025	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO								
N 021148	009	>A>	8672898	Jan 02, 2022	DP			
		>A>	8684969	Oct 20, 2025	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO								
N 021148	010	>A>	8672898	Jan 02, 2022	DP			
		>A>	8684969	Oct 20, 2025	DP			
SORAFENIB TOSYLATE - NEXAVAR								
N 021923	001		8618141	Feb 11, 2023	U-1480			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO								
N 022239	001	>A>	6174304	Dec 13, 2015	DP			
		>A>	6251091	Dec 09, 2016	DP			
		>A>	6280410	Mar 27, 2017	DP			
		>A>	6681810	Dec 13, 2015	DP			
		>A>	8241243	Aug 10, 2023	DP			
		>A>	8491524	Nov 21, 2022	DP			
TASIMELTEON - HETLIOZ								
N 205677	001		5856529	Dec 09, 2017	DS DP U-1486		NCE	Jan 31, 2019
							ODE	Jan 31, 2021
TEMOZOLOMIDE - TEMODAR								
N 022277	001		8623868	Feb 21, 2023	DP			
TEMSIROLIMUS - TORISEL								
N 022088	001		5362718	Feb 15, 2019	DS DP	Y		
			5362718*PED	Aug 15, 2019				
			RE44768	Feb 15, 2019	DS DP			
			RE44768*PED	Aug 15, 2019				
TESTOSTERONE UNDECANOATE - AVEED								
N 022219	001	>A>	7718640	Mar 14, 2027	DP		>A> NP	Mar 05, 2017
		>A>	8338395	Feb 27, 2026	U-1500			
THALIDOMIDE - THALOMID								
N 020785	001		8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID								
N 020785	002		8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID								
N 020785	003		8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID								
N 020785	004		8626531	Oct 23, 2020	U-1465			
TIMOLOL MALEATE - ISTALOL								
N 021516	001	>A>	6645963	Dec 02, 2018	DP			
TOFACITINIB CITRATE - XELJANZ								
N 203214	001						>A> M-135	Feb 21, 2017
TOLVAPTAN - SAMSCA								
N 022275	001		5753677	May 19, 2020	U-978			
TOLVAPTAN - SAMSCA								
N 022275	002		5753677	May 19, 2020	U-978			
TOLVAPTAN - SAMSCA								
N 022275	003		5753677	May 19, 2020	U-978			
TOPIRAMATE - TROKENDI XR								
N 201635	001		8663683	Nov 16, 2027	DP U-106			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
TOPIRAMATE - TROKENDI XR						
N 201635 003	8663683	Nov 16, 2027	DP U-106			
TOPIRAMATE - TROKENDI XR						
N 201635 004	8663683	Nov 16, 2027	DP U-106			
TOPIRAMATE - QUDEXY XR						
N 205122 001 >A>	8652527	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 002 >A>	8652527	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 003 >A>	8652527	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 004 >A>	8652527	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 005 >A>	8652527	Mar 19, 2033	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001					I-678	Jan 08, 2017
					ODE	Jan 08, 2021
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002					I-678	Jan 08, 2017
					ODE	Jan 08, 2021
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003					I-678	Jan 08, 2017
					ODE	Jan 08, 2021
TREPROSTINIL - REMODULIN						
N 021272 001	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
TREPROSTINIL - REMODULIN						
N 021272 002	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
TREPROSTINIL - REMODULIN						
N 021272 003	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
TREPROSTINIL - REMODULIN						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA						
N 203975 001					NP	Dec 18, 2016
VANDETANIB - CAPRELSA						
N 022405 001	8642608	Feb 06, 2022	U-1490			
VANDETANIB - CAPRELSA						
N 022405 002	8642608	Feb 06, 2022	U-1490			
VARDENAFIL HYDROCHLORIDE - STAXYN						
N 200179 001	8613950	Dec 23, 2028	DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 001 >A>	8673921	Jun 05, 2022	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 002 >A>	8673921	Jun 05, 2022	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 003 >A>	8673921	Jun 05, 2022	DS DP			
VORINOSTAT - ZOLINZA						
N 021991 001 >A>	8450372	Mar 18, 2028	U-892			
ZICONOTIDE ACETATE - PRIALT						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZICONOTIDE ACETATE - PRIALT						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
ZICONOTIDE ACETATE - PRIALT						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
ZICONOTIDE ACETATE - PRIALT						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm